Tumor and serum samples were obtained from pts with solid tumors (bladder, cervical, melanoma, lung, pancreatic, renal cell, head and neck) and lymphoma treated with linrodostat + NIVO during the expansion phase in CA017-003....high IFN-γ gene signature (Ayers et al. J Clin Invest. 2017) was associated with response and improved progression-free and overall survival....IFN-ɣ signature and TDO2 gene expression may be a potential composite biomarker to identify pts with certain tumor types more likely to respond to linrodostat mesylate + NIVO.